Fair Value Measurement - Additional Information (Detail) (USD $)		3 Months Ended
Mar. 31, 2014	Mar. 31, 2013 Novozymes Biopharma DK A/S Sweden Ab	Mar. 31, 2013 Novozymes Biopharma DK A/S Sweden Ab Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$ 0
Fair value of other liabilities	0
Business acquisition, contingent payment			80,000
Fair value adjustment		$ 92,000

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration